S-40503 – (404920-28-1)

S-40503 is an investigational selective androgen receptor modulator (SARM) developed by Kaken Pharmaceuticals for the treatment of osteoporosis. This novel compound exhibits a unique tissue selectivity profile, demonstrating significant anabolic effects on bone tissue while having minimal impact on muscle mass and no observable effect on the prostate gland.

In preclinical studies, S-40503 has been shown to increase bone mineral density and biomechanical strength in rat models of osteoporosis. Unlike traditional androgens such as testosterone, S-40503 does not cause prostate enlargement, making it a potentially safer alternative for both men and women. The compound’s ability to stimulate bone formation without virilizing side effects suggests it could address unmet needs in osteoporosis treatment, particularly for patients at high risk of fractures.

Despite its promising initial results, further development of S-40503 for human use has not been reported, and it is speculated that the compound may serve as a lead for the development of new derivatives with improved pharmacokinetic properties.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/S-40503
https://pubchem.ncbi.nlm.nih.gov/compound/9879175
https://www.medchemexpress.com/s-40503.html
https://www.medkoo.com/products/15849
https://pubmed.ncbi.nlm.nih.gov/14600402/
https://www.bioworld.com/articles/572379-s-40503-a-novel-sarm-with-selective-effects-on-bone-in-rat-models-of-osteoporosis?v=preview
https://www.researchgate.net/publication/9024742_Bone_Anabolic_Effects_of_S-40503_a_Novel_Nonsteroidal_Selective_Androgen_Receptor_Modulator_SARM_in_Rat_Models_of_Osteoporosis